Your browser doesn't support javascript.
loading
High-throughput bactericidal assays for monoclonal antibody screening against antimicrobial resistant Neisseria gonorrhoeae.
Stazzoni, Samuele; Troisi, Marco; Abbiento, Valentina; Sala, Claudia; Andreano, Emanuele; Rappuoli, Rino.
Afiliação
  • Stazzoni S; Monoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences, Siena, Italy.
  • Troisi M; Monoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences, Siena, Italy.
  • Abbiento V; Monoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences, Siena, Italy.
  • Sala C; Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.
  • Andreano E; Monoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences, Siena, Italy.
  • Rappuoli R; Monoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences, Siena, Italy.
Front Microbiol ; 14: 1243427, 2023.
Article em En | MEDLINE | ID: mdl-37655342
ABSTRACT
Neisseria gonorrhoeae (gonococcus) is an obligate human pathogen and the etiological agent of the sexually transmitted disease gonorrhea. The rapid rise in gonococcal resistance to all currently available antimicrobials has become a significant public health burden and the need to develop novel therapeutic and prophylactic tools is now a global priority. While high-throughput screening methods allowed rapid discovery of extremely potent monoclonal antibodies (mAbs) against viral pathogens, the field of bacteriology suffers from the lack of assays that allow efficient screening of large panels of samples. To address this point, we developed luminescence-based (L-ABA) and resazurin-based (R-ABA) antibody bactericidal assays that measure N. gonorrhoeae metabolic activity as a proxy of bacterial viability. Both L-ABA and R-ABA are applicable on the large scale for the rapid identification of bactericidal antibodies and were validated by conventional methods. Implementation of these approaches will be instrumental to the development of new medications and vaccines against N. gonorrhoeae and other bacterial pathogens to support the fight against antimicrobial resistance.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Screening_studies Idioma: En Revista: Front Microbiol Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Screening_studies Idioma: En Revista: Front Microbiol Ano de publicação: 2023 Tipo de documento: Article